Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-104016
Filing Date
2025-08-06
Accepted
2025-08-06 16:10:04
Documents
1
Period of Report
2025-08-05

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3914
  Complete submission text file 0000950170-25-104016.txt   5401
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Issuer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 188 EAST BLAINE STREET SUITE 400 SEATTLE WA 98102
Business Address
Rosiello Robert L. (Reporting) CIK: 0001645041 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37465 | Film No.: 251189630